JP2012506051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506051A5 JP2012506051A5 JP2011532094A JP2011532094A JP2012506051A5 JP 2012506051 A5 JP2012506051 A5 JP 2012506051A5 JP 2011532094 A JP2011532094 A JP 2011532094A JP 2011532094 A JP2011532094 A JP 2011532094A JP 2012506051 A5 JP2012506051 A5 JP 2012506051A5
- Authority
- JP
- Japan
- Prior art keywords
- lipoprotein
- insulin resistance
- parameters
- risk
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004895 Lipoproteins Human genes 0.000 claims 29
- 108090001030 Lipoproteins Proteins 0.000 claims 28
- 206010022489 Insulin Resistance Diseases 0.000 claims 26
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 22
- 239000002245 particle Substances 0.000 claims 13
- 238000005259 measurement Methods 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 10
- 238000005481 NMR spectroscopy Methods 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 4
- 238000004590 computer program Methods 0.000 claims 3
- 235000020925 non fasting Nutrition 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004891 communication Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10683308P | 2008-10-20 | 2008-10-20 | |
| US61/106,833 | 2008-10-20 | ||
| PCT/US2009/005689 WO2010047767A2 (en) | 2008-10-20 | 2009-10-20 | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506051A JP2012506051A (ja) | 2012-03-08 |
| JP2012506051A5 true JP2012506051A5 (enExample) | 2012-12-06 |
| JP5393798B2 JP5393798B2 (ja) | 2014-01-22 |
Family
ID=42109358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532094A Active JP5393798B2 (ja) | 2008-10-20 | 2009-10-20 | リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8386187B2 (enExample) |
| EP (2) | EP4016105A1 (enExample) |
| JP (1) | JP5393798B2 (enExample) |
| KR (1) | KR20110086074A (enExample) |
| AU (1) | AU2009308124B2 (enExample) |
| CA (1) | CA2741034C (enExample) |
| WO (1) | WO2010047767A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010047767A2 (en) | 2008-10-20 | 2010-04-29 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
| WO2013003454A2 (en) * | 2011-06-30 | 2013-01-03 | Liposcience, Inc. | Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges |
| JP6308954B2 (ja) * | 2012-03-05 | 2018-04-11 | オサケユキテュア・アークティック・パートナーズ・アクチボラゲットＯｙ Ａｒｃｔｉｃ Ｐａｒｔｎｅｒｓ Ａｂ | 前立腺癌のリスク及び前立腺容積を予測する方法及び装置 |
| US9483611B2 (en) | 2012-04-27 | 2016-11-01 | Liposcience, Inc. | Protective HDL particle number evaluations |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| US9551768B2 (en) | 2013-03-15 | 2017-01-24 | East Carolina University | NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease |
| JP6696907B2 (ja) * | 2014-01-06 | 2020-05-20 | リポサイエンス，インコーポレイテッド | 糖尿病への転化を予測する多重マーカリスクパラメータ |
| CN114740202A (zh) | 2014-03-28 | 2022-07-12 | 欧普科诊断有限责任公司 | 与前列腺癌的诊断有关的组合物和方法 |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| CN107110939B (zh) * | 2014-09-11 | 2021-05-14 | 力保科学公司 | 用于测定心血管疾病或事件的风险参数的系统 |
| CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| EP3253800B1 (en) | 2015-03-27 | 2021-03-03 | Opko Diagnostics, LLC | Prostate antigen standards and uses thereof |
| CA2982262A1 (en) | 2015-04-29 | 2016-11-03 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| KR102539142B1 (ko) | 2016-09-05 | 2023-06-01 | 삼성전자주식회사 | 스펙트럼 분석 장치와 방법, 및 혈당 측정 장치 |
| US10775458B2 (en) | 2018-03-05 | 2020-09-15 | Texas Tech University System | Method and system for non-invasive measurement of metabolic health |
| WO2021062298A1 (en) | 2019-09-27 | 2021-04-01 | Arterez, Inc. | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
| WO2022089749A1 (en) * | 2020-10-29 | 2022-05-05 | Telefonaktiebolaget Lm Ericsson (Publ) | Checking state consistency in a log replication configuration |
| CN113117241B (zh) * | 2021-04-15 | 2022-01-28 | 中国科学院合肥物质科学研究院 | 一种提高胰岛素水平和敏感性的磁场发生装置及其应用 |
| CN115188493A (zh) * | 2022-07-13 | 2022-10-14 | 天津市人民医院 | 一种胰岛素抵抗预测模型的构建系统、方法及应用 |
| WO2024097429A1 (en) * | 2022-11-05 | 2024-05-10 | Texas Tech University System | Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals |
| CN120613144B (zh) * | 2025-05-27 | 2026-02-03 | 中国科学院精密测量科学与技术创新研究院 | 一种基于血液nmr编辑谱的药物敏感度预测方法 |
| CN120280166A (zh) * | 2025-06-10 | 2025-07-08 | 南昌大学第二附属医院 | 术后胰岛素抵抗风险预测模型的构建方法及系统 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933844A (en) | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| AU2384292A (en) | 1991-07-30 | 1993-03-02 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
| US6653140B2 (en) * | 1999-02-26 | 2003-11-25 | Liposcience, Inc. | Methods for providing personalized lipoprotein-based risk assessments |
| EP1171778B1 (en) * | 1999-04-22 | 2006-03-01 | Liposcience, Inc. | Nmr-method for determining the risk of developing type 2 diabetes |
| US7395158B2 (en) * | 2000-05-30 | 2008-07-01 | Sensys Medical, Inc. | Method of screening for disorders of glucose metabolism |
| US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| US6617167B2 (en) * | 2001-08-01 | 2003-09-09 | Liposcience, Inc. | Method of determining presence and concentration of lipoprotein X in blood plasma and serum |
| CA2467420A1 (en) * | 2001-11-13 | 2003-05-22 | The Regents Of The University Of California | Ion mobility analysis of biological particles |
| AU2003285926A1 (en) * | 2002-10-25 | 2004-05-25 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| DE10315877B4 (de) * | 2003-04-08 | 2005-11-17 | Roche Diagnostics Gmbh | Krankheitsverlaufkontrolle |
| FR2853911B1 (fr) * | 2003-04-17 | 2005-07-08 | Merck Sante Sas | Gene induit par l'insuline, comme cible therapeutique dans le diabete |
| CA2539430C (en) * | 2003-09-23 | 2015-03-17 | The General Hospital Corporation | Screening for gestational disorders with sex hormone binding globulin as biomarker |
| AU2005230449B2 (en) * | 2004-04-01 | 2010-02-18 | Liposcience, Inc. | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
| US9372190B2 (en) * | 2004-05-26 | 2016-06-21 | Region Nordjylland | Method of evaluation of the relative risk of developing atherosclerosis in patients |
| DE102004026903B4 (de) * | 2004-06-01 | 2006-05-18 | Universität Regensburg | Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür |
| HUE029170T2 (en) * | 2004-07-20 | 2017-03-28 | Genentech Inc | Preparations and methods for the use of angiopoietin-like protein 4 |
| JP4210855B2 (ja) * | 2004-09-28 | 2009-01-21 | 大塚製薬株式会社 | インスリン抵抗性の評価方法 |
| US7323296B2 (en) * | 2004-10-01 | 2008-01-29 | Yuanhong Ma | Method and index for diagnosing insulin resistance |
| EP1645877A1 (en) * | 2004-10-08 | 2006-04-12 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Method for providing a insulin resistance biomarker profile of one or more lipids |
| EP1872138A1 (en) * | 2005-04-11 | 2008-01-02 | AstraZeneca AB | A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes. |
| WO2007133593A2 (en) * | 2006-05-10 | 2007-11-22 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements |
| EP2164977B1 (en) * | 2007-07-17 | 2013-10-30 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods using the same |
| US20090191576A1 (en) * | 2008-01-28 | 2009-07-30 | Yuanhong Ma | Method and index for diagnosing insulin resistance |
| WO2010047767A2 (en) | 2008-10-20 | 2010-04-29 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
-
2009
- 2009-10-20 WO PCT/US2009/005689 patent/WO2010047767A2/en not_active Ceased
- 2009-10-20 US US12/582,259 patent/US8386187B2/en active Active
- 2009-10-20 EP EP21190653.2A patent/EP4016105A1/en not_active Ceased
- 2009-10-20 KR KR1020117011307A patent/KR20110086074A/ko not_active Ceased
- 2009-10-20 AU AU2009308124A patent/AU2009308124B2/en not_active Expired - Fee Related
- 2009-10-20 CA CA2741034A patent/CA2741034C/en active Active
- 2009-10-20 EP EP09822305.0A patent/EP2344890B1/en active Active
- 2009-10-20 JP JP2011532094A patent/JP5393798B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cerezuela‐Espejo et al. | Are we ready to measure running power? Repeatability and concurrent validity of five commercial technologies | |
| Crotty et al. | Reliability and validity of the lactate pro 2 analyzer | |
| Merry et al. | The validity and reliability of two commercially available load sensors for clinical strength assessment | |
| JP2015522806A5 (enExample) | ||
| JP2015524917A5 (enExample) | ||
| Wang et al. | Characterization of human plasma proteome dynamics using deuterium oxide | |
| De Simone et al. | Allometric normalization of cardiac measures: producing better, but imperfect, accuracy | |
| Watkins et al. | Concurrent validity and reliability of three ultra-portable vertical jump assessment technologies | |
| Araujo-Moura et al. | Blood pressure measurement in pediatric population: comparison between automated oscillometric devices and mercury sphygmomanometers—a systematic review and meta-analysis | |
| JP2012515898A5 (enExample) | ||
| CN107945878A (zh) | 一种基于放射组学的肝静脉压力梯度计算模型的构建方法 | |
| Held et al. | Reliability of the maximal lactate accumulation rate in rowers | |
| JP5199685B2 (ja) | 健康診断の検査値換算プログラム | |
| JP2021508048A5 (enExample) | ||
| Rodrigues Filho et al. | Evaluating the impact of measurement uncertainty in blood pressure measurement on hypertension diagnosis | |
| JP2025066131A (ja) | マルチパラメータ代謝脆弱性指数評価 | |
| Cai et al. | Association Between Cardiovascular Biological Age and Cardiovascular Disease―A Prospective Cohort Study― | |
| Drobnič et al. | The validity of a three-dimensional motion capture system and the garmin running dynamics pod in connection with an assessment of ground contact time while running in place | |
| Tang et al. | Metabolite Fusion between Breath and Blood Enables More In-Depth Understanding of the Endogenous Metabolome | |
| Knight et al. | Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome | |
| TW201516725A (zh) | 單一核苷酸多型性疾病發生率預測系統 | |
| Eriksen et al. | A maximal cycle test with good validity and high repeatability in adults of all ages | |
| US20170316176A1 (en) | Device for analyzing insulin secretion ability, system for analyzing insulin secretion ability provided with same, and method for analyzing insulin secretion ability | |
| JP2009050596A (ja) | 腹囲推定装置 | |
| US8380297B2 (en) | System for measuring a user's percentage of body fat |